1
|
|
2
|
van der Hiele K, van Gorp DAM, Heerings MAP, van Lieshout I, Jongen PJ, Reneman MF, van der Klink JJL, Vosman F, Middelkoop HAM, Visser LH. The MS@Work study: a 3-year prospective observational study on factors involved with work participation in patients with relapsing-remitting Multiple Sclerosis. BMC Neurol 2015; 15:134. [PMID: 26264389 PMCID: PMC4531500 DOI: 10.1186/s12883-015-0375-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Accepted: 07/08/2015] [Indexed: 12/05/2022] Open
Abstract
Background Multiple Sclerosis (MS) is the most common cause of neurological disability in young and middle-aged adults. At this stage in life most people are in the midst of their working career. The majority of MS patients are unable to retain employment within 10 years from disease onset. Leading up to unemployment, many may experience a reduction in hours or work responsibilities and increased time missed from work. The MS@Work study examines various factors that may influence work participation in relapsing-remitting MS patients, including disease-related factors, the working environment and personal factors. Methods/design The MS@Work study is a multicenter, 3-year prospective observational study on work participation in patients with relapsing-remitting MS. We aim to include 350 patients through 15–18 MS outpatient clinics in the Netherlands. Eligible participants are 18 years and older, and either currently employed or within three years since their last employment. At baseline and after 1, 2 and 3 years, the participants are asked to complete online questionnaires (including questions on work participation, work problems and accommodations, cognitive and physical ability, anxiety, depression, psychosocial stress, quality of life, fatigue, empathy, personality traits and coping strategies) and undergo cognitive and neurological examinations. After six months, patients are requested to only complete online questionnaires. Patient perspectives on maintaining and improving work participation and reasons to stop working are gathered through semi-structured interviews in a sub-group of patients. Discussion Prospective studies with long-term follow-up on work participation in MS are rare, or take into account a limited number of factors. The MS@Work study provides a 3-year follow-up on various factors that may influence work participation in patients with relapsing-remitting MS. We aim to identify factors that relate to job loss and to provide information about preventative measures for physicians, psychologists and other professionals working in the field of occupational health.
Collapse
Affiliation(s)
- Karin van der Hiele
- National Multiple Sclerosis Foundation, Mathenesserlaan 378, Rotterdam, 3023HB, The Netherlands. .,Department of Psychology, Section Health, Medical and Neuropsychology, Leiden University, PO Box 9555, Leiden, 2300 RB, The Netherlands. .,Department of Neurology, St. Elisabeth-TweeSteden Hospital, PO Box 90151, Tilburg, 5000 LC, The Netherlands.
| | - Dennis A M van Gorp
- National Multiple Sclerosis Foundation, Mathenesserlaan 378, Rotterdam, 3023HB, The Netherlands. .,Department of Psychology, Section Health, Medical and Neuropsychology, Leiden University, PO Box 9555, Leiden, 2300 RB, The Netherlands. .,Department of Neurology, St. Elisabeth-TweeSteden Hospital, PO Box 90151, Tilburg, 5000 LC, The Netherlands. .,University of Humanistic Studies, PO Box 797, Utrecht, 3500 AT, The Netherlands.
| | - Marco A P Heerings
- National Multiple Sclerosis Foundation, Mathenesserlaan 378, Rotterdam, 3023HB, The Netherlands.
| | - Irma van Lieshout
- van Lieshout Arbo Advies, PO Box 325, Uden, 5400 AH, The Netherlands.
| | - Peter J Jongen
- MS4 Research Institute, Ubbergseweg 34, Nijmegen, 6522 KJ, The Netherlands. .,Department of Community & Occupational Medicine, University Medical Center Groningen, Ant. Deusinglaan 1, PO Box 30001, Groningen, 9713 AV, The Netherlands.
| | - Michiel F Reneman
- University Medical Centre Groningen, Centre for Rehabilitation, University of Groningen, PO Box 30.002, Haren, 9750 RA, The Netherlands.
| | - Jac J L van der Klink
- Department of Social and Behavioral Sciences, Tranzo Scientific Center for Care and Welfare, Tilburg University, PO Box 90153, Tilburg, 5000 LE, The Netherlands.
| | - Frans Vosman
- University of Humanistic Studies, PO Box 797, Utrecht, 3500 AT, The Netherlands.
| | - Huub A M Middelkoop
- Department of Psychology, Section Health, Medical and Neuropsychology, Leiden University, PO Box 9555, Leiden, 2300 RB, The Netherlands. .,Department of Neurology, Leiden University Medical Centre, PO Box 9600, Leiden, 2300 RC, The Netherlands.
| | - Leo H Visser
- Department of Neurology, St. Elisabeth-TweeSteden Hospital, PO Box 90151, Tilburg, 5000 LC, The Netherlands. .,University of Humanistic Studies, PO Box 797, Utrecht, 3500 AT, The Netherlands.
| | | |
Collapse
|
3
|
de la Pena I, Pabon M, Acosta S, Sanberg PR, Tajiri N, Kaneko Y, Borlongan CV. Oligodendrocytes engineered with migratory proteins as effective graft source for cell transplantation in multiple sclerosis. CELL MEDICINE 2014; 6:123-127. [PMID: 24999443 DOI: 10.3727/215517913x674144] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Multiple sclerosis (MS) is characterized by widespread immunomodulatory demyelination of the CNS resulting in nerve cell dysfunction. Accordingly, treatment strategies have been centered on immunodulation and remyelination, with the former primarily focused on reducing the pathology rather than enhancing myelin repair which the latter targets. While conceding to the emerging view of heterogeneity in the pathology of MS, which precludes variations in degree of immune response (i.e., inflammation) and demyelination, the concept of enhancing myelin repair is appealing since it is likely to provide both disease-reducing and disease-inhibiting therapeutic approach to MS. In this regard, we and several others, have proposed that cell replacement therapy is an effective strategy to repair the myelin in MS. Here, we hypothesize that transplantation of mouse bone marrow-derived oligodendrocytes (BMDOs) and BMDOs transfected with Ephrin proteins (BMDO+Ephrin), which are known to enhance cell and axonal migratory capacity, may produce therapeutic benefits in animal models of MS.
Collapse
Affiliation(s)
- Ike de la Pena
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair. University of South Florida, Morsani College of Medicine 12901 Bruce B. Downs Blvd., Tampa, FL 33612
| | - Mibel Pabon
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair. University of South Florida, Morsani College of Medicine 12901 Bruce B. Downs Blvd., Tampa, FL 33612
| | - Sandra Acosta
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair. University of South Florida, Morsani College of Medicine 12901 Bruce B. Downs Blvd., Tampa, FL 33612
| | - Paul R Sanberg
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair. University of South Florida, Morsani College of Medicine 12901 Bruce B. Downs Blvd., Tampa, FL 33612
| | - Naoki Tajiri
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair. University of South Florida, Morsani College of Medicine 12901 Bruce B. Downs Blvd., Tampa, FL 33612
| | - Yuji Kaneko
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair. University of South Florida, Morsani College of Medicine 12901 Bruce B. Downs Blvd., Tampa, FL 33612
| | - Cesar V Borlongan
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair. University of South Florida, Morsani College of Medicine 12901 Bruce B. Downs Blvd., Tampa, FL 33612
| |
Collapse
|
4
|
Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, Lindzen E, Salter A, Frohman TC, Shah A, Bates A, Cox JL, Dwyer MG, Stüve O, Greenberg BM, Racke MK, Zivadinov R. A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2011; 3:15-28. [PMID: 21180633 DOI: 10.1177/1756285609353354] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Mycophenolate mofetil (MMF, CellCept®) has been utilized as an antirejection agent in transplant recipients and in patients with myriad autoimmune disorders including multiple sclerosis (MS). OBJECTIVE To investigate radiographic and clinical safety involving monotherapy use of daily oral MMF (1 g b.i.d.) versus weekly intramuscular interferon beta 1a (Avonex® at 30 mcg) in relapsing-remitting MS (RRMS). METHODS We organized a randomized, serial, 6-monthly, MRI-blinded, parallel-group multicenter pilot study to determine the safety of MMF versus interferon beta monotherapy in 35 untreated patients with RRMS, all of whom exhibited evidence of gadolinium (Gd) enhancement on a screening MRI of the brain. The primary outcome was the reduction in the cumulative mean number of combined active lesions (CAL), new Gd-enhancing lesions, and new T2 lesions on MRI analyses. RESULTS Both interferon beta and MMF appeared safe and well tolerated in the majority of patients. There was no difference between MMF therapy and the standard regimen of interferon beta therapy on the primary safety MRI endpoints of the study. However, the MMF group showed a trend toward a lower accumulation of combined active lesions, CAL, Gd and T2 lesions when compared with interferon beta treated patients. CONCLUSIONS The results from this pilot study suggest that the application of MMF monotherapy in MS deserves further exploration.
Collapse
Affiliation(s)
- Elliot M Frohman
- Departments of Neurology and Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Abstract
Multiple sclerosis (MS) is regarded as a prototypic inflammatory autoimmune central nervous system disorder causing neurological disability in young adults. Recommended basic immunomodulatory therapies of MS are currently interferon beta and glatiramer acetate. Both have proven to be clinically and paraclinically effective and clinical evidence suggests that treatment should be initiated as early as possible. However, despite the fact that therapeutic options for MS have significantly been widened over the past decade there is still tremendous activity in the search for new treatment options for MS. One important development in the field is reflected by the substantial number of promising results for oral therapies. Various phase III clinical trials are currently being initiated or are already underway evaluating the efficacy of a variety of orally administered agents, including cladribine, teriflunomide, laquinimod, fingolimod and fumaric acid. It is hoped that these oral therapies for MS further broaden our armament for MS therapy.
Collapse
|
6
|
Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol 2009; 77:1757-62. [PMID: 19428330 DOI: 10.1016/j.bcp.2009.01.007] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2008] [Revised: 01/13/2009] [Accepted: 01/15/2009] [Indexed: 02/03/2023]
Abstract
Restoration of dysregulated bone homeostasis is a therapeutic goal in many diseases including osteoporosis, rheumatoid arthritis and metastatic cancer. The molecular pathways regulating bone remodeling are major therapeutic targets, and studies continue to reveal endogenous factors that may be pathologically up- or down-regulated and lead to an uncoupling of bone formation and resorption. The purpose of this commentary is to highlight new mechanisms of bone homeostatic regulation mediated through the induction of endogenous interferon-beta (IFN-beta). The receptor activator of nuclear factor-kappaB (RANK) ligand (RANKL) is an important factor in the bone resorption cascade, and the RANK-RANKL interaction has been shown to induce IFN-beta and osteoclastogenesis via induction of the c-fos gene. Subsequent binding of IFN-beta to its biological receptor initiates a signal transduction cascade through the classic JAK/STAT pathway, causing an inhibition of c-fos protein production and osteoclast proliferation and differentiation (negative feedback). Another mechanism pertinent to the anti-resorptive effect of IFN-beta is the induction of nitric oxide which has been shown to inhibit osteoclast formation. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Here we also provide discussion of the potential challenges to optimizing IFN-beta pharmacotherapy for such purposes.
Collapse
|
7
|
|
8
|
Payne N, Siatskas C, Bernard CC. The promise of stem cell and regenerative therapies for multiple sclerosis. J Autoimmun 2008; 31:288-94. [DOI: 10.1016/j.jaut.2008.04.002] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
9
|
Ziemssen T, Hoffman J, Apfel R, Kern S. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes 2008; 6:67. [PMID: 18775064 PMCID: PMC2542355 DOI: 10.1186/1477-7525-6-67] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2008] [Accepted: 09/05/2008] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVES Treatment of multiple sclerosis patients with glatiramer acetate has been demonstrated a beneficial effect on disease activity. The objective of this prospective naturalistic study was to evaluate the impact of glatiramer acetate on fatigue and work absenteeism. METHODS 291 treatment-naïve patients with relapsing remitting multiple sclerosis were included and treated with glatiramer acetate for twelve months. Relapse rates, disability, fatigue symptoms, days of absence from work and adverse events were monitored. Fatigue was measured with the MFIS scale and with a visual analogue scale. RESULTS Total MFIS scores decreased by 7.6 +/- 16.4 from 34.6 to 27.0 (p < or = 0.001). Significant reductions were observed on all three subscales of the MFIS. Fatigue symptoms, assessed using a visual analogue scale, decreased by 1.04 +/- 2.88 cm from 4.47 cm to 3.43 cm (p < or = 0.001). The proportion of patients absent from work at least once was reduced by a factor of two from 65.1% to 30.1% (p < or = 0.001). Tolerance to treatment was rated as very good or good in 78.3% of patients. Adverse effects, most frequently local injection site reactions, were reported in 15.1% of patients. CONCLUSION Treatment with glatiramer acetate was associated with a significant improvement in fatigue symptoms and a marked reduction in absence from work. Treatment was well-tolerated. Such benefits are of relevance to overall patient well-being.
Collapse
Affiliation(s)
- Tjalf Ziemssen
- MS Center, Neurological University Clinic, Technical University of Dresden, Dresden, Germany.
| | | | | | | |
Collapse
|
10
|
Rao DVK, Ramu CT, Rao JV, Narasu ML, Rao AKSB. Cloning, high expression and purification of recombinant human intereferon-beta-1b in Escherichia coli. Appl Biochem Biotechnol 2008; 158:140-54. [PMID: 18679594 DOI: 10.1007/s12010-008-8318-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2008] [Accepted: 07/09/2008] [Indexed: 11/24/2022]
Abstract
Sequential evaluation and process control strategy were employed for impurity profile and high recovery with quality of rhIFN-beta-1b expressed in Escherichia coli. The high-level expression was achieved by using codon substitution (AT content of 52.6% at N-terminal region) and optimization of culture conditions. The addition of rifampicin at a concentration of 200 microg/ml has increased the specific product yield of 66 mg optical density(-1) l(-1) (43.5% of total cellular protein). Eighty-three percent of lipopolysaccharides, 32% of host deoxyribonucleic acid (DNA), and 78% of host cell proteins were removed by 0.75% Triton X-100 and 2 M urea wash. Eleven percent of lipopolysaccharides, 39% of host DNA, and 12% of host cell proteins were removed at the solubilization step. Ninety-two percent of protein refolding was achieved by high-pressure diafiltration method. Refolding by high-pressure diafiltration, bed height, and height equivalent to the theoretical plate value in chromatography column were identified as key parameters for high recovery with purity. Finally, the established process yielded 34% of purified protein with greater than 99% purity and is acceptable for preclinical toxicological studies. The purified rhIFN-beta-1b obtained in this study is the highest that has been reported so far.
Collapse
|
11
|
Minden S, Hoaglin D, Jureidini S, Hadden L, Frankel D, Komatsuzaki Y, Outley J. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study. Mult Scler 2008; 14:640-55. [DOI: 10.1177/1352458507086463] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background Although experts recommend that people with multiple sclerosis (MS) should begin treatment with disease-modifying agents (DMAs) as soon as possible after diagnosis and continue indefinitely, many do not use these agents or discontinue them prematurely. Since DMAs reduce relapse rates and slow disease progression, and since even benign relapses and course can lead to axonal damage and permanent neurologic impairment, it is important that all appropriate candidates have access to treatment. We used a population-based sample of people with MS to determine rates, predictors, and reasons for use, non-use, and discontinuation of DMAs. Methods We collected data from 2156 people with MS on their use of and experience with DMAs. We used chi-squared tests to compare current, past, and never users of any DMA and ever users of individual DMAs, and logistic regression to identify predictors of use. Results One-half of the participants were using a DMA at the time of the interview; 12.2% had used previously, but stopped. Reasons for never using and reasons for stopping were at odds with expert recommendations. Characterization of users, and of their experiences by type of DMA, was consistent with current knowledge of these agents. Seeing a neurologist for usual MS care was an important factor in starting and persisting with DMA therapy. Conclusions Dissemination of expert opinion about, and management strategies for, use of DMAs to non-neurologic professionals and patients and their families might help more people who are appropriate candidates for DMA therapy to start and continue treatment.
Collapse
Affiliation(s)
- S Minden
- Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA,
| | - D Hoaglin
- Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA
| | - S Jureidini
- Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA
| | - L Hadden
- Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA
| | - D Frankel
- Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA
| | - Y Komatsuzaki
- Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA
| | - J Outley
- Brigham and Women’s Hospital, Boston, MA, USA and Abt Associates Inc., Cambridge, MA, USA
| |
Collapse
|
12
|
Frohman E, Costello F, Zivadinov R, Stuve O, Conger A, Winslow H, Trip A, Frohman T, Balcer L. Optical coherence tomography in multiple sclerosis. Lancet Neurol 2006; 5:853-63. [PMID: 16987732 DOI: 10.1016/s1474-4422(06)70573-7] [Citation(s) in RCA: 116] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
We do not have currently satisfactory clinical and anatomical correlates to gauge disability in multiple sclerosis. Structural biomarkers (such as MRI) are hindered because they cannot precisely segregate demyelination from axonal elements of tissue injury within the CNS. Axonal degeneration in multiple sclerosis is related to irreversible disability, which suggests that the confirmation of neuroprotective strategies needs highly quantifiable measures of axon loss that can be correlated with reliable measures of physiological function. The coupling of quantifiable measures of visual function with ocular imaging techniques, such as optical coherence tomography, enables us to begin to understand how structural changes in the visual system influence function in patients with multiple sclerosis. In this review, we consider the usefulness of optical imaging of the retina as a biomarker for neurodegeneration in multiple-sclerosis.
Collapse
Affiliation(s)
- Elliot Frohman
- Department of Neurology, University of Texas Southwestern Medical Center at Dallas, 75235, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Tsoi VL, Hill KE, Carlson NG, Warner JEA, Rose JW. Immunohistochemical evidence of inducible nitric oxide synthase and nitrotyrosine in a case of clinically isolated optic neuritis. J Neuroophthalmol 2006; 26:87-94. [PMID: 16845306 DOI: 10.1097/01.wno.0000223266.48447.1b] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Optic neuritis (ON) is a demyelinating inflammation of the optic nerve that may occur as an isolated disease or related to multiple sclerosis (MS). There is little evidence of whether the immunohistochemistry of ON resembles that of typical cerebral MS lesions. METHODS Pathologic optic nerves were obtained from a patient who died of causes unrelated to ON after clinical recovery from clinically isolated ON. Normal control optic nerves were obtained from an eye bank. Normal and pathologic tissues were probed with antibodies to pathologic proteins including myelin basic protein (MBP) fragment, the inducible form of nitric oxide synthase (iNOS), macrophage markers CD14 and CD64, nitrotyrosine, and cyclooxygenase (COX-2). We also examined MBP, the oligodendrocyte marker cyclic nucleotide phosphodiesterase (CNPase), and glial fibrillary acidic protein. RESULTS In the affected pathologic nerve, iNOS-positive macrophages/microglia, iNOS-positive astrocytes, COX-2, and nitrotyrosine were observed. iNOS and COX-2 were occasionally observed in the unaffected nerve. Decreased expression of MBP and CNPase was seen in the pathologic optic nerves, along with evidence of gliosis and ongoing myelin degradation indicated by the presence of MBP fragment. CONCLUSIONS The immunohistochemistry of clinically isolated optic neuritis, as judged by this single case, resembles that of cerebral lesions of MS in showing abnormally high levels of iNOS and nitrotyrosine as well as other mediators of immune damage.
Collapse
Affiliation(s)
- Veda L Tsoi
- Neurovirology Research Laboratory, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah 84148, USA
| | | | | | | | | |
Collapse
|
14
|
Opdenakker G. Immunohistopathology to guide multiple sclerosis treatment. Lancet 2005; 366:526-7. [PMID: 16099274 DOI: 10.1016/s0140-6736(05)67076-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Ghislain Opdenakker
- Immunobiology, Rega Institute for Medical Research, University of Leuven, B-3000 Leuven, Belgium.
| |
Collapse
|
15
|
Montú MB, Arruda WO, de Oliveira MDSR, Ramina R. Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients. ARQUIVOS DE NEURO-PSIQUIATRIA 2005; 63:225-7. [PMID: 16100967 DOI: 10.1590/s0004-282x2005000200007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Mitoxantrone hydrochloride (Novantrone®) is an anthracenedione that has been used as one of the latest in a long line of general immunosuppresive agents studied in multiple sclerosis (MS). We reviewed the clinical, laboratory, neuroimaging and echocardiography data of 18 patients from February 2001 to March 2004 out of a total number of 100 patients with definite MS. Fourteen patients were women (77.7%) and four were men. The mean age of the patients was 41.6±10 years old (confidence intervals 95%: 36.4-46.7 years old). The mean duration of disease was 10.5±6.3 years. Fourteen patients had the secondarily progressive form of MS, and four had the relapsing-remitting form. Mitoxantrone is an useful and clinically effective drug in MS and its major limitation is the potencial cardiotoxicity due to cumulative dose (140 mg).
Collapse
|
16
|
Abstract
Subcutaneous recombinant interferon-beta-1a (Rebif) 22 or 44 microg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis (RRMS). It has shown benefits on outcome measures related to relapses, progression of disability and magnetic resonance imaging (MRI) in clinical trials. A significant efficacy advantage for subcutaneous interferon-beta-1a three times weekly over intramuscular interferon-beta-1a 30 microg once weekly was shown at 24 and 48 weeks. The most common adverse events are generally mild and clinically manageable. Considering both direct and indirect comparative clinical trial data, an assessment suggests that subcutaneous interferon-beta-1a 44 microg three times weekly has the best benefit-to-risk values of the available disease-modifying drugs used to treat RRMS.
Collapse
|
17
|
Kalanie H, Gharagozli K, Hemmatie A, Ghorbanie M, Kalanie AR. Interferon Beta-1a and Intravenous Immunoglobulin Treatment for Multiple Sclerosis in Iran. Eur Neurol 2004; 52:202-6. [PMID: 15539773 DOI: 10.1159/000082036] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2004] [Accepted: 09/08/2004] [Indexed: 11/19/2022]
Abstract
The aim of the study was to evaluate the efficacy and safety of interferon beta-1a (Avonex) and intravenous immunoglobulin (IVIG) in clinical practice for the treatment of relapsing-remitting multiple sclerosis. Avonex is the most common disease-modifying therapy used in Iran due to its ease of administration. IVIG is also frequently used due to its alleged effectiveness and fewer side effects. Eighty patients were selected and prospectively monitored according to a predefined protocol. They were then randomized to receive either weekly intramuscular injections of Avonex or 0.4 g/kg monthly IVIG in a single blind fashion and following an attack of exacerbation which was treated with steroids. Basal relapse rate and Expanded Disability Status Scale (EDSS) were similar in both groups of patients (p > 0.4). Seventy-two patients remained in the study. The annual relapse rate consistently decreased from 0.95 +/- 0.41 to 0.60 +/- 0.67 (approximately 32%, p < 0.001) for 34 patients treated with Avonex and from 1.05 +/- 0.34 to 0.55 +/- 0.46 for 38 patients in the IVIG group (approximately 47%, p < 0.001). EDSS decreased by 0.4 units in IVIG-treated patients (p < 0.001) and remained stable (0.2 < p < 0.3) in the Avonex arm. This study confirms the relative efficacy of both treatments with better safety profile for IVIG in the studied Iranian population. However, the results are very preliminary ones, due to limited numbers of patients and only 12 months of treatment.
Collapse
Affiliation(s)
- Hossein Kalanie
- Shahid Beheshtie University of Medical Sciences, Department of Neurology, Loghman Hospital, Tehran, Iran.
| | | | | | | | | |
Collapse
|
18
|
Ozminkowski RJ, Marder WD, Hawkins K, Wang S, Stallings SC, Finkelstein SN, Sinskey AJ, Wierz D. The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. Clin Ther 2004; 26:1341-54. [PMID: 15476915 DOI: 10.1016/s0149-2918(04)80225-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVES The aims of this study were to estimate the effects of demographics, location, severity of multiple sclerosis (MS), comorbidities, plan type, coinsurance levels, and time of entry into the sample on the use of disease-modifying agents. METHODS A retrospective analysis of medical claims data from 1996 through 2000 was conducted with a sample of MS patients covered by self-insured, employer-sponsored health plans. Proportional hazard analysis with the SAS procedure for proportional hazards regression was used to estimate the impact of the factors of interest on the use of disease-modifying agents. A simulation was conducted to assess the impact of changing drug copayments on the use of disease-modifying agents for MS. RESULTS The sample included 1807 patients. Patients were followed for as long as possible, but most were observed for <3 years; the mean (SD) follow-up time was 972.88 (440.59) days. Most factors associated with the use of disease-modifying agents were immutable. They included the following: high severity of illness (only marginally related; P = NS); history of seizures (P = 0.03), depression (P < 0.01), or heart disease (P = 0.01); census region of location (P < 0.01); union membership or association with a union member (P < 0.01); drug copayment requirements (P < 0.05); and year of entry into the sample (P < 0.01). In the simulation, a 50% reduction in drug copayments was associated with an increase of the proportion of patients treated with disease-modifying drugs from 41.2% to 54.7%. Patients' and physicians' preferences for treatment could not be measured directly. The true onset of MS may be unknown for many patients, but this would be the case even if medical records or other data were used for this study. CONCLUSIONS Our analyses showed an association between copayments and the use of disease-modifying drugs for MS. Insurance policies can be tailored to influence the use of disease-modifying drugs, enhancing the quality of care for MS patients and reducing price-related barriers to beneficial treatment. Future research should test whether reducing copayments for MS treatment would reduce the use of other health care services (via better MS treatment that modifies the course of illness), or whether the use of disease-modifying drugs would increase total costs to the plan, resulting in slightly higher premiums.
Collapse
Affiliation(s)
- Ronald J Ozminkowski
- Health and Productivity Management Research, Medstat, Ann Arbor, Michigan 48108, USA.
| | | | | | | | | | | | | | | |
Collapse
|